Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBRATE phase 3 study of encaleret versus standard of care in autosomal dominant hypocalcemia type 1
2022-501398-38-00Phase 3Authorised
- Sponsor
- Calcilytix Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial in autosomal dominant hypocalcemia type 1 (ADH1) comparing Encaleret with Standard of care (2 arms). Primary endpoint: Responder status. Planned start Sep 2023; status: authorised.
02
Drugs
encaleret
03
Conditions
autosomal dominant hypocalcemia type 1 (ADH1)
Beyond the preview
Go deeper on 2022-501398-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501398-38-00.